Ambrosioni, JuanCoiras, MayteAlcamí, JoséMiró, José María2019-02-122019-02-122017Expert Rev Anti Infect Ther. 2017 May;15(5):421-423.1478-7210http://hdl.handle.net/20.500.12105/7170engVoRhttp://creativecommons.org/licenses/by-nc-sa/4.0/HIVTKITyrosine kinase inhibitorsAcute/recent infectionDasatinibPrimary infectionViral reservoirsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesDasatinibGene Expression RegulationHIV InfectionsHIV-1HumansLymphocyte ActivationPhosphorylationProtein Kinase InhibitorsProtein-Tyrosine KinasesPotential role of tyrosine kinase inhibitors during primary HIV-1 infectionAtribución-NoComercial-CompartirIgual 4.0 Internacional28322065155421-42310.1080/14787210.2017.13088231744-8336Expert review of anti-infective therapyopen access